News AstraZeneca PLC

Equities

AZN

GB0009895292

Market Closed - London S.E. Other stock markets 11:35:29 2024-05-02 am EDT			5-day change	1st Jan Change
12,156 ^GBX	-0.12%		+7.88%	+14.68%

05:18pm	AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial	MT
04:46pm	AstraZeneca: research into respiratory diseases	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial	11:18am	MT
AstraZeneca: research into respiratory diseases	10:46am	CF
AstraZeneca : Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial - Form 6-K	09:04am	PU
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	07:04am	BU
AstraZeneca Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	07:00am	CI
AstraZeneca PLC Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	07:00am	CI
AstraZeneca: encouraging results in lymphoma	05:24am	CF
AstraZeneca notes positive trial results for Calquence treatment	05:06am	AN
AstraZeneca's Blood Cancer Combo Extends Progression-free Survival in Late-stage Study	03:01am	MT
Ipsen: new President for North America	02:58am	CF
AstraZeneca PLC Announces Calquence combination improved PFS in 1L MCL	02:00am	CI
Astrazeneca Joins Hands With Partners to Tackle Kenya's Cancer Burden	May. 01	AQ
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio	May. 01	BU
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition	Apr. 30	AQ
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
ASTRAZENECA : Deutsche Bank gives a Neutral rating	Apr. 30	ZD

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT